Successful Full-Service, Randomized Pancreatic Cancer Phase II Trial

Learn more now about how one clinical-stage biopharma company successfully closed Phase II and advanced to Phase III for their multi-center, randomized study of a modified synthetic peptide in patients with exocrine pancreatic cancer. Discover how they leveraged support from Veristat to overcome challenges and drive their research forward.

Explore how the company successfully addressed:

Slow recruitment challenges
Data cleaning needs, post mid-study updates
Managing a high volume of site documents across 20 study sites
Managing uncommunicated staff and site changes across study sites
Resolving data collection, monitoring, and filing process differences

Register for the case study

Your Company Email Address

Please select your industry: (max 1)

Opt In?

By completing this form you agree Citeline and Veristat may contact you directly about industry news, products, services and events that may be of interest to you subject to the privacy policies of Citeline and Veristat.